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Abstract
In patients with Parkinson’s disease (PD), the associated pathology follows a characteristic pattern involving inter alia the
enteric nervous system (ENS), the dorsal motor nucleus of the vagus (DMV), the intermediolateral nucleus of the spinal cord
and the substantia nigra, providing the basis for the neuropathological staging of the disease. Here we report that
intragastrically administered rotenone, a commonly used pesticide that inhibits Complex I of the mitochondrial respiratory
chain, is able to reproduce PD pathological staging as found in patients. Our results show that low doses of chronically and
intragastrically administered rotenone induce alpha-synuclein accumulation in all the above-mentioned nervous system
structures of wild-type mice. Moreover, we also observed inflammation and alpha-synuclein phosphorylation in the ENS and
DMV. HPLC analysis showed no rotenone levels in the systemic blood or the central nervous system (detection limit
[rotenone],20 nM) and mitochondrial Complex I measurements showed no systemic Complex I inhibition after 1.5 months
of treatment. These alterations are sequential, appearing only in synaptically connected nervous structures, treatment time-
dependent and accompanied by inflammatory signs and motor dysfunctions. These results strongly suggest that the local
effect of pesticides on the ENS might be sufficient to induce PD-like progression and to reproduce the neuroanatomical and
neurochemical features of PD staging. It provides new insight into how environmental factors could trigger PD and
suggests a transsynaptic mechanism by which PD might spread throughout the central nervous system.
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Introduction
Parkinson’s Disease (PD) is a highly prevalent disease affecting
0.3% of the general population and 1–3% of the population over
the age of 65 [1]. PD is slowly progressive, and is characterized by
dysfunction of the somatomotor system (i.e., rigidity, bradykinesia,
postural instability, gait dysfunction and tremor), which usually
dominates the clinical picture of sporadic PD [2]. The main
symptoms are caused by the progressive degeneration of the
nigrostriatal dopaminergic pathway [3,4] These complaints,
however, are often preceded or accompanied by other symptoms
that also emerge during the disease course [5,6,7]. Hyposmia and
gastrointestinal alterations are among the non-motor signs that
develop early, often preceding motor symptoms by years
[8,9,10,11], and are normally accompanied by autonomic
dysfunction [12,13] as well as the experience of pain [14,15].
A pathological hallmark of PD is the accumulation of
filamentous, cytoplasmic inclusions consisting mainly of alpha-
synuclein aggregations in the form of Lewy bodies (LB) or Lewy
neurites (LN) [16,17]. They are found in certain areas of the
central nervous system (CNS), e.g. the dorsal motor nucleus of the
vagus (DMV), the intermediolateral nucleus in the spinal cord
(IML), the locus coeruleus (LC) and the olfactory bulb (OB), and of
the peripheral nervous system (PNS) e.g., celiac ganglia and ENS,
of PD patients [18,19,20,21]. These pathological findings are
usually associated with an inflammatory response [22] and
phosphorylation of the alpha-synuclein (Ser129) which accumu-
lates as a component of LB in the brains of patients with alpha-
synucleinopathies [23].
Although genetic mutations contribute to the development of
rare familial forms of PD (e.g. mutations in alpha-synuclein,
Parkin, LRRK2, PINK1 genes) [24,25,26] most of the cases are
sporadic and due to unclear aetiologies. It has been postulated that
mitochondrial dysfunction [27], oxidative stress [28], inflamma-
tory response [29] and protein mishandling may play an important
role in the pathogenesis of sporadic PD [30]. On the other hand,
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pesticides and the incidence of PD [31].
Many studies have used different pesticides and routes of
administration in order to reproduce pathological and clinical
findings of PD in animals [32]. These models show different
combinations of the clinical and pathological features of PD, such
as the selective loss of TH-positive neurons, the presence of LB in
the SN, impaired striatal dopaminergic innervation or motor
dysfunction. Nevertheless, they fail to reproduce the complete
spectrum of pathological disease progression and provide little
information on the risk of environmental exposure because these
methods bypass the physical and metabolic defences of the
organism. Moreover, systemic administration of rotenone in
C57BL/6J mice has failed to reproduce any of the pathological
features of PD [33].
Braak and colleagues have suggested that the pathological
process starts in the ENS and OB progressing into the CNS
through anatomically connected structures [21]. Interestingly, it
has been shown that alpha-synuclein oligomeres can be endocy-
tosed by neurons and induce alpha-synuclein aggregation in
primary neuronal cultures [34,35]. Moreover, Desplats and
colleagues have shown inclusion formation and neuronal cell
death through neuron-to-neuron transport of alpha-synuclein both
in vivo and in vitro [36]. In our study we wanted to investigate
whether the local effect of ingested pesticides (orally administered)
on the intestinal track could induce alpha-synuclein accumulation
in the ENS and thereby induce PD-like pathological progression
predicted by Braak’s model.
Results
In order to test whether the local effect on the ENS of an orally
administered pesticide could reproduce the progression of PD
predicted by Braak’s model, we decided to administer rotenone
intragastrically to one-year old mice using a gastric tube.
Method Validation
To determine that rotenone did not reach the systemic blood or
the CNS, we performed HPLC analysis on blood, brain and
brainstem samples of non-experimental C57BL/6J mice exposed
to rotenone before starting the experiments. Blood samples were
extracted from 8 week-old mice treated with 2.5, 5, 10 and
20 mg/kg rotenone for 7 days. Brain and brainstem samples were
obtained from one-year old mice treated with 5, 10 and 20 mg/kg
rotenone for 7 days. We were unable to detect rotenone via HPLC
in the blood at doses of 5 mg/kg or lower and in the brainstem or
brain at doses of 10 mg/kg or lower (Figure S1). Therefore, we
decided to use a dose of 5 mg/kg rotenone to treat experimental
mice. HPLC analysis made on weeks 2, 4 and 10 of treatment
showed the same results (data not shown).
Rotenone is an extremely potent mitochondrial Complex I
inhibitor. In order to further confirm the systemic absence of
rotenone, we decided to measure mitochondrial Complex I
activity in brain and muscle samples. The results showed no
mitochondrial Complex I activity reduction in muscle or brain of
1.5 months treated mice when compared to the controls (Figure
S1).
Rotarod Test
To investigate whether treated mice showed motor dysfunction,
we performed an accelerating rotarod test, which provides a more
discriminating way to correlate motor deficits against lesion size
[37]. The results of the rotarod test, performed with an initial
speed of 4 rpm and an acceleration of 0.3 rpm/sec, showed a
significant decrease (p,0.05) in the rodent’s ability to remain on
the rod between 3 month treated mice and controls, but not
between the performance of 1.5 month treated mice and controls
(Figure S1). No difference was found between the treated groups
and controls when an acceleration of 0.2 rpm/sec was used (data
not shown).
We then examined whether there were alpha-synuclein PD-like
alterations in ENS, IML, DMV or the SN and if these alterations
were progressive.
Effects of Rotenone on the ENS
We detected alpha-synuclein in ENS neurons from the
duodenum and ileum of both control and treated animals.
However, the distribution, inclusion number and amount of
alpha-synuclein differed between treated and control animals.
Control mice showed alpha-synuclein mainly in the periphery of
the neuronal soma (Figure 1A) while in treated mice, the amount
of alpha-synuclein was increased and it was present both inside
and outside the neural soma (Figure 1B), with larger alpha-
synuclein accumulations ( .6 mm) in 20% of the analyzed
ganglia after 3 months treatment (Figure 1C). To investigate
whether alpha-synuclein was aggregated, we double stained with
alpha-synuclein and Thioflavine-S, a marker for b-sheet formation
within filamentous aggregates. We observed alpha-synuclein
aggregation only in the larger accumulations identified in mice
treated for 3 months (Figure 1D). Associated alpha-synuclein
phosphorylation and gliosis was confirmed by the presence of
GFAP and Ser-129 phosphorylated alpha-synuclein in ENS
ganglia from treated (Fig. 1H and 1J) but not control mice
(Figure 1G and 1I). Immunohistochemical staining for alpha-
synuclein using an alternative alpha-synuclein antibody (Syn-1)
confirmed the presence of synuclein staining within ganglia of
ENS. No specific staining with AT8 antibody (phosphorylated tau
marker) was detected and control immunostaining using only
secondary antibodies showed no unspecific staining.
Image analysis using Image J Software showed that the total
surface stained with alpha-synuclein inside the ganglia and the
number of inclusions significantly increased in the duodenum and
ileum after 1.5 months rotenone treatment when compared to
controls (p,0.01) (Figure 1E and 1F). Interestingly, the value of
these parameters decreased after 3 months treatment coinciding
with the appearance of larger inclusions of aggregated alpha-
synuclein (Figure 1C).
The Local Effect of Rotenone on the ENS Leads to Alpha-
Synuclein Accumulation in the IML and the DMV
Next, we wanted to determine whether the local effect of
rotenone on the ENS could lead to alterations in the synaptically
connected autonomic nervous system centers in the spinal cord
and the brainstem (the IML and the DMV). Indeed, PD related
pathological changes were detected in both sites. We observed an
increase in alpha-synuclein and some large alpha-synuclein
intracellular inclusions (2% of the analyzed images) in ChAT
+
neurons of IML ( .7.5 mm) (Figure 2A–C) as well as increased
alpha-synuclein staining in the dorsal horn layer I after 1.5 and 3
months treatment (Figure 2G and 2H) when compared to controls.
In order to test whether there was a correlation between alpha-
synucleinpathologyandcell deathinIMLneurons, weanalyzed the
ChAT
+ neuronal population in the IML. Our results showed that
even after 3 months of treatment there was no significant difference
in the mean number of IML cholinergic neurons per section
between treated (3.839 6 0.2196, n=5) and control (3.607 6
0.2065, n=5) mice.
PD Pathology Progression
PLoS ONE | www.plosone.org 2 January 2010 | Volume 5 | Issue 1 | e8762Figure 1. Locally administered rotenone induces alpha-synuclein phosphorylation, accumulation and aggregation with gliosis in
ENS ganglia. (scale bars 20 mm). A, B, C, anti bIII-tubulin, alpha-synuclein and DAPI staining in duodenum (B) and ileum (A,C) sections. Arrow in B,
1.5 months treatment induced an increased alpha-synuclein punctate pattern inside enteric nervous system ganglia when compared to 3 months
controls (A). Arrow in C, 3 months treatment induced formation of larger alpha-synuclein inclusions (|.6 mm). D, immunofluorescence staining using
anti-alpha-synuclein, Thioflavine S and DAPI. Arrow in D, only 3 month treated mice showed aggregation of these larger alpha-synuclein
accumulations. E, F, quantification of the experiment shown in A–C was made using automatic segmentation and entropy-based thresholding
methods. Single-asterisk, P,0.05, and double-asterisk, P,0.01. E, each column represents total alpha-synuclein surface/ganglion surface. F, each
column represents total number of alpha-synuclein inclusions/ganglion surface. All graphs show mean 6 s.e.m. G, H, max-projection of staining
against GFAP, alpha-synuclein and DAPI on duodenum sections from control (G) and treated (H) mice. I, J, max-projection of anti-bIII-tubulin, anti-
phospho-alpha-synuclein (Ser 129) and DAPI staining on duodenum sections from control (I) and treated (J) animals.
doi:10.1371/journal.pone.0008762.g001
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by measuring fluorescence in the IML. Fluorescence measure-
ments showed that the IML/IML adjacent region ratio of alpha-
synuclein mean fluorescence intensity was increased in both 1.5
month (p,0.01) and 3 month-treated mice (p,0.01) when
compared to controls (Figure 2D–F), thus suggesting an increase
in alpha-synuclein in preganglionic sympathetic neuron pro-
cesses. This difference was not observed in ChAT
+ motor
neurons of the anterior horn (Figure S2). These results were
confirmed by immunohistochemistry on DAB stained sections,
where the intensity of alpha-synuclein staining was greater in
tissue sections from 3 month treated animals when compared to
control sections (Figure S2). There were no differences in GFAP
staining between treated and control mice in this area (data not
shown).
In the DMV, 1.5 and 3 months rotenone treatment resulted in
increased intracellular alpha-synuclein accumulation inside
ChAT
+ neurons (Figure 3B) when compared to controls
(Figure 3A). We also observed an inflammatory associated
reaction, with increased GFAP and some activated microglial
cells around neurons of the DMV in treated but not control mice
(Figure 3G and 3H). Remarkably, ChAT
+ neurons from adjacent
hypoglossus nuclei showed neither alpha-synuclein accumulations
nor GFAP increase (data not shown). Control immunostaining
with secondary antibodies showed auto-fluorescent inclusions
inside DMV neurons from treated mice only (Figure 3C). Previous
studies have identified auto-fluorescent inclusions as lipofuscin
accumulations [38]. Lipofuscin granules mainly contain lipids.
Therefore we used Sudan IV staining and confirmed them as
lipofuscin inclusions (data not shown). In order to avoid auto-
Figure 2. Intracellular and axonal alpha-synuclein increases in the intermediolateral nucleus and the dorsal horn lamina I layer of
the spinal cord after oral rotenone treatment. (scale bars 20 mm) A, B, C, Immunostaining against alpha-synuclein and choline acetyl
transferase (ChAT) in spinal cord sections showing the intermediolateral nucleus ChAT
+ neurons from 3 months control mice (A), 1.5 months (B) and
3 months (C) treated mice. Arrow in B, colocalization of increased intracellular alpha-synuclein and ChAT
+ stainings in the IML. Arrow in C, large
alpha-synuclein inclusion (|.7.5 mm) inside an IML ChAT
+ neuron. D–E, fluorescence intensity color-coded images from 3 months control (D, D’) and
3 months treated mice (E, E’) spinal cord sections stained using DAPI and alpha-synuclein and ChAT antibodies. Arrows in D and E, areas in the
proximity of ChAT
+ neurons. F, mean fluorescence quantification of experiment shown in D and E. Double asterisk, P,0,01. Columns represent mean
alpha-synuclein fluorescence in and around ChAT
+ neurons in the IML/mean alpha-synuclein fluorescence in the region anterior to the IML. Graph
shows mean 6 s.e.m.. G, H, DAB-staining against apha-synuclein using synuclein-1 antibody in the dorsal horn of the spinal cord from 3 months
treated (H) and control (G) mice. Arrows in G–H, lamina I layer of the dorsal horn.
doi:10.1371/journal.pone.0008762.g002
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istry with DAB detection of alpha-synuclein on 1.5 and 3 months
treated mice. This technique also showed alpha-synuclein
accumulation in DMV neurons when compared to controls
(Figure 3D–F). Alpha-synuclein was detected in both, neurons and
the neuropil, however only in treated animals the staining of
neural processes was visible (Figure 3F).
Finally, we analyzed the effect of rotenone treatment on the
ChAT
+ neuronal population in the DMV. Again, even after 3
months treatment no significant difference in the total number of
cholinergic neurons between treated (1932 6 294.7, n=5) and
control (1632 6 281.3, n=5) mice was detected.
Altogether, these results suggest that both directly (DMV) and
indirectly (IML) with the ENS synaptically connected structures
harbour accumulated alpha-synuclein after rotenone administra-
tion. However, accumulation of alpha-synuclein in these areas
does not affect neuronal population in terms of cell loss.
Alpha-Synuclein Pathology Progresses into the SN after
Three Months Oral Rotenone Treatment
In order to investigate whether other PD-related CNS structures
were affected, we analyzed the SN and the striatum of rotenone-
treated and control mice. In the SN, we observed an increase in
intracellular alpha-synuclein (Figure 4B) together with larger alpha-
synuclein accumulations in the substantia nigra pars compacta (SNc)
(Figure 4c) similarly to that within DMV and IML. Remarkably we
also observed a significant 15.4% decrease (p,0.05) in the number
of TH
+ neurons (Figure 4D) in 3 month but not 1.5 month treated
mice when compared to controls (Figure 4A).
The decrease in dopaminergic neurons could also be explained
by a down regulation of the dopamine rate-limiting synthesizing
enzyme tyrosine hydroxylase (TH). Therefore, we also performed
a double-staining using DAB detection of TH together with Nissl’s
staining to quantify the total number of neurons in this area after
three-month treatment in both groups (Figure S3A and S3B). We
observed an increase in the amount of SNc cells in both groups
(Figure S3C). This increase was significantly higher in treated mice
than in control mice (Figure S3D). Interestingly, we also observed
that the decrease in Nissl
+ neurons between 3-month control and
treated mice was 19% smaller than the decrease in TH
+ neurons
(Figure S3E). Altogether, these results suggest that together with a
loss of TH
+ neurons there are some dopaminergic neurons that
might indeed have a lower TH expression and could, therefore,
been missed in the stereological analysis based only on TH
+
neurons.
Figure 3. Intragastrically administered rotenone induces alpha-synuclein accumulation, oxidative stress and inflammation in the
dorsal motor nucleus vagus. (scale bars 20 mm). A, B, double-immunofluorescence staining against alpha-synuclein and ChAT on DMV sections
from 1.5 months control (A) and 1.5 months treated (B) mice. Arrows in B, increased intracellular alpha-synuclein in DMV neurons already after 1.5
months. Arrowheads in B, autofluorescent punctate inclusion pattern inside ChAT
+ neurons. C, DMV sections stained with ChAT and DAPI were
sequentially excited with 488 and 561 laser wavelengths. Arrows in C, large intracellular auto-fluorescent inclusions inside ChAT
+ neurons of the DMV
(arrows). D, E, F, Light microscopy images of alpha-synuclein staining from 1.5 months control (D), 1.5 months (E) and 3 months (F) treated mice.
Arrows in E and F, increased staining intensity inside DMV neuronal soma in treated mice. Arrowheads in F, increased alpha-synuclein staining inside
neuronal processes G, H, average-projection of triple-immunofluorescence staining against ChAT, GFAP, MHC II (clone M5/114.15.2) and DAPI on
sections from control (G) and treated (H) mice after 3 month treatment. Arrow in H, activated microglial cell in the DMV.
doi:10.1371/journal.pone.0008762.g003
PD Pathology Progression
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innervation of the striatum (Figure 4E–F), brain tau protein,
lipofucsin granules or alpha-synuclein accumulation in other brain
areas (e.g. cerebellum, cortex or striatum) (data not shown) between
treated and control animals at any time-point, confirming that
observed changes in alpha-synuclein accumulation and aggregation
are confined within selected pathways of the intestine-cerebral axis.
Discussion
It has been proposed that the PD-related inclusion body
pathology in the nervous system progresses in six stages, starting at
the OB and the ENS and affecting closely connected neural sites
[39,40]. Interestingly, the OB and the ENS are the only nervous
system structures directly exposed to environmental substances.
Figure 4. Alpha-synuclein accumulation and neuronal loss in the SNc after 3 but not 1.5 months intragastrical rotenone treatment.
(A–C, scale bars 20 mm; E–F, scale bars 200 mm). A, B, C, immunostaining against TH, alpha-synuclein and DAPI on SNc sections from 1.5 months
control (A) and 3 months (B–C) treated mice. Arrow in B, alpha-synuclein small inclusions inside TH
+ neurons. Arrow in C, large alpha-synuclein
inclusion (|.8.14 mm) inside a dopamineric neuron in the SN. D, stereological quantification (n=3) of TH
+ neurons in the SN from control and treated
mice. Asterisk, P,0.05. Number of neurons was determined based on the optical fractionator principle using StereoInvestigator software
(MicroBrightField Inc., Williston, USA). Each column represents total number of TH
+ neurons in the SN in 1.5 and 3 months control and treated mice.
Graph shows mean 6 s.e.m. E, F, TH immunostaining on striatum in 1.5 months control (E) and 3 months treated (F) mice.
doi:10.1371/journal.pone.0008762.g004
PD Pathology Progression
PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8762Recently developed PD animal toxic models fail to reproduce
the entire pathological spectrum of the disease. Moreover, they
also avoid the important physiological defence mechanisms to
external substances [32,41,42].
Actual reports concerning patients with PD who received
transplants of embryonic mesencephalic neurons show that in
some cases, mesencephalic neurons grafted into the striatum of PD
patients develop both alpha-synuclein and ubiquitin positive LB
[43,44,45]. According to these and other evidence [46], Brundin
and colleagues proposed inflammation, oxidative stress, excitotox-
icity, prion-disease-like mechanisms and loss of neurotrophic
support as possible underlying mechanisms for PD propagation
[47]. Interestingly, Desplats and colleagues have recently shown
inclusion formation and neuronal cell death through neuron-to-
neuron transport of alpha-synuclein both in vivo and in vitro [36].
Our results show that chronic treatment with intragastrically
administered rotenone reproduces some of the reported PD
pathological features – accumulation and aggregation of alpha-
synuclein within ENS, DMV, IML and SN. These alterations
occur without detectable levels of the pesticide in the blood or the
brain and no inhibition of Complex I activity in muscle or brain
even after 1.5 months of treatment. The HPLC method we
employed was able to detect as little as 20 nM rotenone, but we
were unable to detect rotenone in the blood with 5 mg/kg
treatment, or in the CNS with 10 mg/kg treatment, see Results),
which argues against systemic effect of rotenone being a causative
factor for observed changes. Also, the results from other studies
using animal models with higher systemic concentrations of
rotenone [33,48] and the absence of systemic Complex I inhibition
speak against this possibility. Richter and colleagues have shown
that subcutaneous administration of 2.5–4 mg/kg of rotenone for
30–40 days does not induce striatal degeneration or neuronal loss
in the CNS of C57BL/6J mice. On the other hand, Betarbet and
colleagues observed striatum degeneration before the SN was
affected with the lowest dose (2.5 mg/kg) and treatment time (7
days) of systemically administered rotenone in rats, suggesting
greater sensitivity of striatal nerve terminals. Remarkably, they did
not observe degeneration anywhere else in the CNS.
We observed alpha-synuclein accumulation, phosphorylation,
and inflammatory signs and loss of nigral TH
+ neurons in our
treated mice after 3 months of the treatment. Moreover, we also
observed intracellular auto-fluorescent Sudan-IV
+ lipofuscin
inclusions. Lipofuscin has been considered a biomarker for
oxidative stress and its presence may suggest an increase in
oxidative stress and the accumulation of advanced glycation end
products [49]. The inflammation pattern observed indicates that
inflammation might not be involved in the propagation of the
alteration but is perhaps a consequence of neuronal damage or
alpha-synuclein accumulation in situ. We have also detected
specificity in the nervous structures affected and only neuronal
subpopulations that have direct connections to ENS showed
alterations while nearby areas remained unaffected. We did not
observe any alterations in the OB, striatal TH or brain tau protein
levels as reported in other rotenone models [48,50,51], suggesting
greater selectivity of the neuronal damage in our model.
Interestingly, the accumulation and aggregation of alpha-
synuclein in the DMV and the IML did not result in neuronal
death. However, we did detect a selective loss of dopaminergic
neurons in the SN after three but not 1.5 months of treatment.
One other explanation for this loss of nigral dopaminergic neurons
could be the down regulation of TH expression in the
dopaminergic cells. Therefore, we also performed a Nissl staining.
Our results show that, although there is also a significant decrease
in the total number of Nissl+ cells in the SNc between treated and
control mice, this difference is smaller than that between TH
+
neurons. Thus, suggesting that there exists a percentage of
dopaminergic neurons with decreased TH expression. These
results indicate that there is an increased sensitivity of central
dopaminergic neurons to the accumulation of intracellular alpha-
synuclein when compared to DMV and IML neurons. However,
there was a non-significant decrease in the number of neurons at
the latter sites, indicating that longer treatment periods may lead
to significant reductions in the neuronal population.
Rotenone treatment resulted in measurable changes in motor
coordination, as detected by differences in the rotarod test
performance. This difference was only observed after 3 months
of treatment – at the same time that neuronal loss in the SN was
detected. Moreover, there seems to be a correlation between the
percentage of dopaminergic loss (between 12% and 15.4%) and
the difference observed in the rotarod test (13.3%). Rotarod test’s
results in rotenone models of PD could be somewhat controversial.
This controversy is based on the difficulty to separate the effect of
dopamine loss in the CNS and the effect of systemic inhibition of
mitochondrial Complex I activity on the motor functions and the
spontaneous motor activity of the mice [33]. Precisely because we
did not observe systemic Complex I activity inhibition in our
model, we believe these concerns are not applicable to our model.
Nevertheless, these results are intriguing, as it is very unlikely that
neuronal loss in the sustantia nigra alone without a reduction in
striatal dopamine could be responsible for these alterations. The
accelerating protocol used has been described to be a more
discriminative test to correlate motor deficits against lesion size,
and might therefore be more sensitive to small alterations.
Unfortunately, the small amount of tissue available did not allow
us to measure dopamine levels in the striatum of treated mice.
Recently, it has been shown that systemic administration of
rotenone in rats also induces alpha-synuclein inclusions in the ENS
[52]. Thus, partially corroborating our results. However, this
model fails to reproduce the progression of the disease as
alterations in the ENS and the CNS occur simultaneously due
to the systematic effect of rotenone, and they do not show DMV or
IML alterations. Also, alpha-synuclein containing processes and
neurons extensively innervate the ENS in rats [53], differing from
the mouse.
Although further mechanistic studies are necessary (i.e.
strategically-placed nervous system lesions), these results strongly
support an enteric nervous system spread hypothesis. The
selectivity of neuronal alterations and the appearance of alpha-
synuclein accumulation in the SN only at the latest treatment time-
point allows us to speculate with the possibility of a direct
mechanism responsible for this remarkable pattern of progression.
Although the precise mechanism remains unclear, recently
published data suggest that alpha-synuclein could be transported
between the cells in vitro and in vivo, inducing its aggregation in
recipient cells [36].
To our knowledge, this is the first animal model capable of
reproducing the progression of PD-like pathology after acting
solely on the ENS. Therefore, we strongly believe that this new
animal model of the disease provides a better tool for
understanding the mechanisms underlying the pathophysiology
of PD and may help to pin-point novel pathways for therapeutic
intervention.
Materials and Methods
Animal Procedures
One-year old C57BL/6J mice (Janvier, France) were housed at
room temperature under a 12-h light/dark cycle. Food and water
PD Pathology Progression
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and treated 5 days a week for 1.5 and 3 months. A stomach tube
was used to administer 0.01 ml/g animal weight of rotenone
solution (0.625 mg/ml rotenone (Sigma-Aldrich, Germany), 4%
carboxymethylcellulose (Sigma-Aldrich, Germany) and 1.25%
chloroform (Carl Roth, Germany)) corresponding to a 5 mg/kg
dose. Controls were treated only with the vehicle (4% carboxy-
methylcellulose and 1.25% chloroform). Blood extraction for High
Performance Liquid Chromatography (HPLC) analysis was
obtained from the retina plexus using a glass capillary under
general anaesthesia (0.01 ml/g of Ketamin i.p.). CNS-tissue was
obtained after cervical dislocation. The rotarod test was performed
after 1.5 and 3 month treatment as already described by others
[37]. Briefly, mice were place on a rotating rod with a initial speed
of 4 rpm. The speed of rotation was gradually increased (0,3 rpm/
sec) and the rodent’s ability to remain on the rotating rod (time to
the first fall) was recorded. The test was repeated three times a day
on each animal over three consecutive days. All animal
experiments were carried out in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals, and protocols were approved by the Saxonian Commit-
tee for Animal Research, Germany.
Measurement of Rotenone Levels in Plasma and CNS
from Mice
Blood from 8 week old control mice and 8 week old mice
treated with 2.5, 5, 10 or 20 mg/kg rotenone for one week (n=3)
was extracted 1, 2 and 3 hours after rotenone administration and
pooled in the same tube. Serum samples were obtained by
centrifugation at 3000 rpm (Micro 12–24, Hettich Zentrifugen,
Germany). Serum was analysed using a modified HPLC protocol
as previously described [54]. Brain and brainstem from control, 5
(n=3), 10 (n=3) and 20 mg/kg (n=1) rotenone 5 day-treated
one-year old animals were collected 1 and 3 hours after the last
rotenone administration and processed as already described by
others [41]. The detection threshold was determined by adding
different concentrations of rotenone to control plasma before
extraction. The methods were linear over a concentration range
from 10 to 500 ng/ml, the inter-assay precision expressed as
coefficient of variation was ,10%. The limit of detection was
10 ng/ml.
Complex I Activity Measurements
Brain and muscle samples were homogenized in 0.5–1 ml of
buffer (120 mM KCl, 20 mM HEPES, 5 mM MgCl2, 1 mM
EGTA; pH 7.2) supplemented with 5 mg/ml BSA using a small
ultraturrax. The extract was then centrifuged for 6 min at 3000
rpm and the supernatant recentrifuged under the same conditions.
The final supernatant was exposed to three cycles of rapid freeze-
thawing in liquid nitrogen and Complex I activity was measured as
the rotenone sensitive NADH dehydrogenase activity as described
previously [55]. Citrate synthase activity was also measured in the
same homogenates [56]. Complex I activity was related to that of
the mitochondrial marker citrate synthase.
Tissue Preparation for Immunostaining
Mice were killed with an overdose of ketamine and perfused
transcardially with 4% paraformaldehyde in 0.1 M phosphate
buffer (pH 7.4). Brain, spinal cord and gastrointestinal tract were
removed and kept in 4% PFA for 24 h. Tissues were transferred
into 30% sucrose, where they remained until equilibrium. Brains
were then frozen using a shock-freezing technique and stored at
280uC. Brain sections (40 mm) were transferred to a 96 wells plate
filled with a cryoprotectant solution containing 25% ethylene
glycol and 25% glycerin in 0.05 M phosphate and stored at
220uC until free-floating immunostaining was performed. Spinal
cords were separated into their cervical, thoracic and lumbar
parts. The thoracic portion was then divided in three equidistant
portions. Portions of the duodenum and ileum were also removed
from the gastrointestinal tract. Both different spinal cord regions
and gut pieces were then separately and vertically immersed in
Tissue-TekH and stored at 280uC.
Immunohistochemistry
Immunofluorescence was performed on 40 mm (brain and
spinal cord) and 20 mm (gastrointestinal tract) paraformaldehyde
fixed frozen sections. Brain sections were stained using a free-
floating immunostaining technique whereas spinal cord and gut
sections were stained on the slide. Non specific background
staining from CNS sections was blocked overnight at 4uCi n
blocking solution (5% donkey serum (Jackson Immunoresearch
Laboratories), 0.4% Triton-X-PBS), whereas gut sections were
blocked for two hours at room temperature (RT) using 5% donkey
serum in 0.25% Triton-X-PBS. Sections were then incubated with
the primary antibodies for 24 hours at 4uC, washed in PBS,
incubated for one hour at RT with the fluorescent secondary
antibodies, washed in PBS again and mounted using VectashieldH
mounting medium for fluorescence with DAPI (Vectro Laborato-
ries, USA). The following polyclonal primary antibodies were
used: goat anti-ChAT (1:500, Chemicon, USA), sheep anti-TH
(1:1000, Peel freeze, Rogers, AR USA), rabbit anti-alpha-
synuclein (1:400, Santa Cruz, USA); chicken anti-GFAP (1:1000,
Abcam, UK) and rat anti-MHC II clone M5/114.15.2 (1:200, BD
Pharmigen, CA, USA), rabbit anti-phospho-alpha-synuclein
(phospho S129) (1:50, Abcam, UK), chicken anti-bIII-tubulin
(1:500, Novus Biologicals, USA). These were coupled with the
following secondary antibodies: AlexaH 488 donkey anti-rabbit,
AlexaH 488 donkey anti-goat, AlexaH488 donkey anti-rat, AlexaH
555 and AlexaH594 donkey anti-sheep and donkey anti-goat (all
1:500 and from Invitrogen, USA) and 647 donkey anti-chicken
(1:200, Jackson Immunoresearch Laboratories, USA). DAB
immunohistochemistry was done as reported before [57]. Mouse
anti alpha-synuclein (BD Transduction Laboratores, San Jose, CA
USA), rabbit anti-TH (Peel freeze, Rogers, AR USA) or AT8
(Pierce Biotechnology, Rockford, IL USA) primary antibodies
were used at 1:1,000. Counterstaining was performed using a
Nissl’s staining as already described by others [58].
Imaging
Immunostained sections were analysed using a Leica Leitz
DMRD bright field microscope and a Zeiss confocal microscope
(LSM 510, Carl Zeiss, Jena). Z-stacks from immunofluorescent gut
sections were obtained using an Apo-63X objective. A Z-stack was
acquired for 7 consecutive ganglia per gut section/animal, with
1 mm spacing in the Z-direction. The optical resolution limit for
these images was 0.13 mm in the XY direction and 1 mm in the Z
direction. Single images of the IML from spinal cord sections were
acquired using the same microscope equipped with an Apo-25X
objective. The optical resolution limit for these images was
0.48 mm in the XY direction. No additional post-acquisition
manipulations of digital images were done. Digital images were
then processed using ImageJ free software (Rasband, W.S.,
ImageJ, U. S. National Institutes of Health, Bethesda, Maryland,
USA, http://rsb.info.nih.gov/ij/, 1997–2005), where only crop-
ping of the original image and minor adjustment of the brightness
and contrast were performed.
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Immunofluorescence image analysis was made using ImageJ
and performed by a third independent researcher, unaware of
images origin. Z-stacks from gut sections were used for quantifying
the alpha-synuclein droplet size. For each stack, the ganglion
region was selected and isolated. Automatic segmentation of
alpha-synuclein droplets was made using an entropy-based
thresholding method, and operations on binary images. The in-
focus plane for alpha-synuclein droplets was then searched for, by
identifying the plane where droplet total surface was maximal.
This sole plane was used for further analysis. The total alpha-
synuclein surface and inclusion number were measured and
normalized by ganglion/neuron area for statistical analyses. IML
images were used to compute a fluorescence ratio, by normalizing
the alpha-synuclein signal in the IML region by that of adjacent
areas.
Stereological Procedures
Every sixth section was stained against TH or ChAT and alpha-
synuclein and used for stereological analysis. The number of TH
+/
ChAT
+ neurons in the SN and the DMV was estimated using the
Optical Fractionator principle [59,60] with StereoInvestigator
software (MicroBrightField Inc., Williston, USA) on a Zeiss
Axioplan microscope and using a 20X objective. Total TH
+
neuron number (N) was calculated using the formula N 1/4 SQ– ?
(t/h) ? (1/asf) ? 1/ssf, where Q– 1/4 is the total number of cells
counted, t 1/4 is the section thickness, h 1/4 is the height of optical
dissector, asf 1/4 is the area of sampling fraction 1/4 a(frame)/
a(x,y step) and ssf 1/4 is the section sampling fraction.
Semi-Quantitative Neuronal Cell Count on the IML
Spinal cord sections from upper, middle and lower levels of the
thoracic spinal cord were stained against ChAT and alpha-
synuclein. The number of cholinergic neurons in the IML per
section was then counted in 10 sections per level/animal (30
sections per animal) and means were compared.
Statistical Analysis
All data was tested for significance using two-way ANOVA,
significance being p#0.05.
Supporting Information
Figure S1 Motor dysfunction in rotenone treated mice without
detection of rotenone in blood or CNS. A, standard (50 ng/ml)
and chromatogram from brain samples of 20, 10 and 5 mg/kg
treated mice. B and C, quantification of rotenone levels in blood
(B) and CNS (C). B, blood levels 1, 2 and 3 hours after treatment.
Mice were divided in three groups (n=3) and treated with 2.5, 5,
10 and 20 mg/kg rotenone (n=3), 300 ml of blood was extracted
1, 2 and 3 hours after rotenone administration and pooled
together for HPLC analysis. C, mice were treated for one week
once a day with 5 (n=3), 10 (n=3) and 20 (n=1) mg/kg
rotenone, brain and brainstem were extracted 1 and 2 hours after
last administration and prepared for HPLC analysis. D,
mitochondrial Complex I activity in muscle and brain samples
of 1.5 month treated mice. E, F, acceleration rotarod protocols
were performed after 1.5 (E) and 3 (F) months of treatment using
0.3 rpm/sec acceleration rates. * in F is P is ,0.05 taking together
values from the three days, values based on Student’s t test. All
error bars correspond to 6 s.e.m.
Found at: doi:10.1371/journal.pone.0008762.s001 (1.37 MB TIF)
Figure S2 Rotenone administered orally induces alpha-synu-
clein accumulation in the IML but not in the motor neurons from
the anterior horn of the spinal cord. (scale bars 20 mm). A, B, DAB
stained spinal cord sections counterstained with cresoyl violet from
control (A) and treated mice (B). Arrows in A and B, IML region of
the spinal cord. C, D, fluorescence intensity color-coded images of
ChAT+ motor neurons of the anterior horn from control (C) and
treated (D) mice. E, mean fluorescence quantification of
experiment shown in C and D. Columns represent mean alpha-
synuclein fluorescence in and around ChAT+ neurons in the
anterior horn/mean alpha-synuclein fluorescence in the region
posterior to the motor neurons. Graph shows mean 6 s.e.m.
Found at: doi:10.1371/journal.pone.0008762.s002 (3.67 MB TIF)
Figure S3 Rotenone treatment causes neuronal depletion and
TH down-regulation in the SNc. (A, scale bar 80 mm, B, scale bar
20 mm) A, B, DAB against TH stained midbrain sections
counterstained using Nissl’s staining from 3 month treated mice.
Arrowheads in B are Nissl+ but not TH+ neurons, whereas arrows
in B are Nissl+2TH+ neurons. C, stereological quantification of
total TH+ and total Nissl+ neurons in the SNc of 3 month control
and treated mice. D, difference in the total number of cells
between stereological quantification based on Nissl’s and TH
stainings in 3 month control and treated mice. E, neuronal
decrease using DAB against TH (left column) and Nissl stainings
(right column). * in C, D and E is p,0.05, values based on
Student’s t test. All error bars correspond to 6 s.e.m.
Found at: doi:10.1371/journal.pone.0008762.s003 (8.92 MB TIF)
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